Table 1 Clinical characteristics of the COPD cohort, based on data collected at inclusion or during follow-up
From: MAIT cell counts are associated with the risk of hospitalization in COPD
Study participants | All (n = 61) | Never hospitalized (n = 40) | Hospitalized (n = 21) | p-value |
|---|---|---|---|---|
Female/Male, n (%) | 35 (57)/26 (43) | 24 (60)/16 (40) | 11 (52)/10 (48) | 0.597 |
Age at inclusion, median (range), years | 70 (55–76) | 70 (55–75) | 69 (56–76) | 0.701 |
Smoking exposure at inclusion, packyears | 38 (25–44) | 40 (25–45) | 37 (23–40) | 0.324 |
Current smoker/Ex-smoker at inclusion, n (%) | 13 (23)/43 (77) | 7 (20)/28 (80) | 6 (29)/15 (71) | 0.523 |
Baseline FEV1, % predicted | 57 (47–69) | 62 (50–70) | 51 (40–63) | 0.039 |
Baseline FEV1/FVC, ratio % | 49 (40–57) | 50 (41–57) | 44 (36–57) | 0.307 |
Baseline CAT score | 12 (9–16) | 11 (8–16) | 14 (10–17) | 0.074 |
Baseline CAT ≥ 10/CAT < 10, n (%) | 42 (69)/19 (31) | 26 (65)/14 (35) | 16 (76)/5 (24) | 0.561 |
Baseline BMI, median (range) | 25 (17–38) | 25 (18–38) | 26 (17–35) | 0.703 |
Inhaled corticosteroids at inclusion, Y/N, n (%) | 35 (57)/26 (43) | 18 (45)/22 (55) | 17 (81)/4 (19) | 0.013 |
CRP at inclusion (mg/L) | 3.0 (1.4–4.2) | 2.9 (1.3–3.7) | 3.7 (1.7–5.9) | 0.074 |
Leucocyte count at inclusion (× 109/L) | 7.1 (6.0–8.4) | 6.6 (5.8–8.2) | 7.5 (6.7–9.6) | 0.019 |
Heart failure diagnosis at inclusion, Y/N, n (%) | 15 (25)/46 (75) | 7 (17.5)/33 (82.5) | 8 (38)/13 (62) | 0.117 |
Diabetes mellitus at inclusion, Y/N, n (%) | 11 (18)/50 (82) | 5 (12.5)/35 (87.5) | 6 (29)/15 (71) | 0.164 |
Frequent exacerbator, Y/N, n (%) | 10 (16)/51 (84) | 2 (5)/38 (95) | 8 (38)/13 (62) | 0.002 |
GOLD 2017 group, A/B/C/D, n | 18/33/1/9 | 14/24/0/2 | 4/9/1/7 | – |
Death or respiratory insufficiency within 3 years, Y/N, n (%) | 10 (16)/51 (84) | 1 (2.5)/39 (97.5) | 9 (43)/12 (57) | 0.0001 |
Received antibiotics within 3 years, Y/N, n (%) | 38 (62)/23 (38) | 18 (45)/22 (55) | 20 (95)/1 (5) | 0.0001 |
Acute exacerbation(s) within 3 years, Y/N, n (%) | 39 (64)/22 (36) | 21 (52.5)/19 (47.5) | 18 (86)/3 (14) | 0.012 |
Total acute exacerbation days within 3 years, median (range) | 11 (0–140) | 6 (0–89) | 20 (0–140) | 0.004 |
Total hospitalization days within 3 years, median (range) | 0 (0–112) | 0 (0–0) | 9 (1–112) | 0.00000 |
Total days on antibiotics per os, median (range) | 10 (0–145) | 0 (0–35) | 35 (0–145) | 0.00001 |
Total days on intravenous antibiotics, median (range) | 0 (0–34) | 0 (0–0) | 3 (0–34) | 0.00001 |